secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2026-08-13T20:03:18+00:00
Accession:  0001193125-26-349127
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma Q2 2026: neffy revenue $26.2M, net loss $62.3M, cuts 2H expenses
---------------------------------------------------------------------------

- Q2 neffy net product revenue $26.2M; total revenue $33.7M incl. $7.4M supply revenue.
- Net loss $62.3M ($0.63/share); cash $143.8M at June 30, 2026.
- 2H 2026 SG&A+R&D guided $114-126M (cash-based $100-110M); >40% cut in cash SG&A vs 1H.
- Meg Smith appointed CCO effective Aug 17, 2026; field sales expansion complete.
- Phase 2b CSU trial interim data expected Q1 2027; no approved on-demand CSU flare treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/0001193125-26-349127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/spry-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer